1.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GE-196-001, NCT00785694
|
|
2.
|
Phase: Phase III, Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HIS-0611-0602, NCT00406068
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: EORTC-30994, ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, NORDIC-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: B9E-MC-S062, AB 22/00, NCT00146276
|
|
5.
|
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PC B305/04, NCT00209157
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003/081/HP, NCT00213655
|
|
7.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12002, NCT00306150
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0337, S0337, NCT00445601
|
|
9.
|
Phase: Phase III
Type: Health services research
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPI-611, NCT00461591
|
|
11.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-05-001, INS-05-001, NCT00538850, NCT00538850
|
|
12.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-06-007, INS-06-007, NCT00538863
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPI-612, NCT00598806
|
|
14.
|
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: SNF320000-113512/1, KEK101_06, SNF320000-113512/1, SWISSMEDIC2007DR3215, NCT00622973
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6668, EUDRACT: 2007-001943-23, NCT00625664
|
|
16.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VRAM M-20070240, NCT00647569
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102.1, NCT00384891
|
|
18.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6521, EudraCT 2007-007943-29, NCT00694382
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UZG-CUL-UHG-Non-Invasive Bladder Cancer, CUL-UHG-Non-Invasive Bladder Cancer, EU-20870, NCT00729287
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICR-SPARE, SPARE, ISRCTN61126465, EU-20907, ICR-CTSU/2006/10002, NCT00867347
|
|
21.
|
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: NHLBI, Other, Pharmaceutical / Industry
Protocol IDs: 25387, 1 R01 HL95109-01, NCT00876915
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0524, NCT00238420
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WBPDT-577-04, NCT00322699
|
|
24.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCC-PHII-75, 7435, NCI-7435, NCT00365157
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CLCC_GEMCIRAV, INCA-RECF0285, GEMCIRAV, GETUG-CLCC-GEMCIRAV, NCT00556621
|
